Cargando…
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by (68)Ga-PSMA-positron emission tomography/computed tomography ((68)Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871999/ https://www.ncbi.nlm.nih.gov/pubmed/29439481 http://dx.doi.org/10.3390/diagnostics8010016 |
_version_ | 1783309740691947520 |
---|---|
author | Lenzo, Nat P. Meyrick, Danielle Turner, J. Harvey |
author_facet | Lenzo, Nat P. Meyrick, Danielle Turner, J. Harvey |
author_sort | Lenzo, Nat P. |
collection | PubMed |
description | Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by (68)Ga-PSMA-positron emission tomography/computed tomography ((68)Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to have superseded CT, and appears superior to MR imaging, for the detection of metastatic disease. (68)Ga-PSMA PET/CT has the ability to reliably stage prostate cancer at presentation and can help inform an optimal treatment approach. Novel diagnostic applications of (68)Ga-PSMA PET/CT include guiding biopsy to improve sampling accuracy, and guiding surgery and radiotherapy. In addition to facilitating the management of metastatic castrate resistant prostate cancer (mCRPC), (68)Ga-PSMA can select patients who may benefit from targeted systemic radionuclide therapy. (68)Ga-PSMA is the diagnostic positron-emitting theranostic pair with the beta emitter Lutetium-177 PSMA ((177)Lu-PSMA) and alpha-emitter Actinium-225 PSMA ((225)Ac-PSMA) which can both be used to treat PSMA-avid metastases of prostate cancer in the molecular tumor-targeted approach of theranostic nuclear oncology. |
format | Online Article Text |
id | pubmed-5871999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58719992018-03-29 Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer Lenzo, Nat P. Meyrick, Danielle Turner, J. Harvey Diagnostics (Basel) Review Over 90% of prostate cancers over-express prostate specific membrane antigen (PSMA) and these tumor cells may be accurately targeted for diagnosis by (68)Ga-PSMA-positron emission tomography/computed tomography ((68)Ga-PSMA-PET/CT) imaging. This novel molecular imaging modality appears clinically to have superseded CT, and appears superior to MR imaging, for the detection of metastatic disease. (68)Ga-PSMA PET/CT has the ability to reliably stage prostate cancer at presentation and can help inform an optimal treatment approach. Novel diagnostic applications of (68)Ga-PSMA PET/CT include guiding biopsy to improve sampling accuracy, and guiding surgery and radiotherapy. In addition to facilitating the management of metastatic castrate resistant prostate cancer (mCRPC), (68)Ga-PSMA can select patients who may benefit from targeted systemic radionuclide therapy. (68)Ga-PSMA is the diagnostic positron-emitting theranostic pair with the beta emitter Lutetium-177 PSMA ((177)Lu-PSMA) and alpha-emitter Actinium-225 PSMA ((225)Ac-PSMA) which can both be used to treat PSMA-avid metastases of prostate cancer in the molecular tumor-targeted approach of theranostic nuclear oncology. MDPI 2018-02-11 /pmc/articles/PMC5871999/ /pubmed/29439481 http://dx.doi.org/10.3390/diagnostics8010016 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lenzo, Nat P. Meyrick, Danielle Turner, J. Harvey Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer |
title | Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer |
title_full | Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer |
title_fullStr | Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer |
title_full_unstemmed | Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer |
title_short | Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer |
title_sort | review of gallium-68 psma pet/ct imaging in the management of prostate cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871999/ https://www.ncbi.nlm.nih.gov/pubmed/29439481 http://dx.doi.org/10.3390/diagnostics8010016 |
work_keys_str_mv | AT lenzonatp reviewofgallium68psmapetctimaginginthemanagementofprostatecancer AT meyrickdanielle reviewofgallium68psmapetctimaginginthemanagementofprostatecancer AT turnerjharvey reviewofgallium68psmapetctimaginginthemanagementofprostatecancer |